Poised For Growth? This Biotech Is Close To Beginning Key Phase 2a Study With Its Lead Candidate

Tiziana Life Sciences TLSA is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis (SPMS), Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, Crohn's disease and more.

The company is close to starting an important phase 2a study with its lead product – Intranasal Foralumab – for non-active SPMS and has plans to initiate a separate study for Alzheimer's disease (AD). The FDA recently cleared the investigational new drug (IND) application for the drug.

Learn more here:

 

Featured photo by National Cancer Institute on  Unsplash


This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPenny StocksHealth CareMarketsGeneralTiziana Life Sciences
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!